What does Dr. Vulsteke Christof, medische oncologie do?

Dr. Vulsteke Christof, medische oncologie is a specialist medical practice in Deerlijk. Private Limited, started on 22 May 2017, 1 establishment.

What is the address of Dr. Vulsteke Christof, medische oncologie?

The registered office of Dr. Vulsteke Christof, medische oncologie is located at Generaal Deprezstraat 2 D, 8540 Deerlijk.

Is Dr. Vulsteke Christof, medische oncologie still active?

Yes. According to the CBE (31 October 2026) Dr. Vulsteke Christof, medische oncologie is active, legal situation “Normale toestand”, started on 22 May 2017.

Is Dr. Vulsteke Christof, medische oncologie registered on Peppol?

Yes, Dr. Vulsteke Christof, medische oncologie is registered on the Peppol network with ID 0208:0675919556.

What is the enterprise number of Dr. Vulsteke Christof, medische oncologie?

The enterprise number of Dr. Vulsteke Christof, medische oncologie is BE0675919556.

When was Dr. Vulsteke Christof, medische oncologie founded?

Dr. Vulsteke Christof, medische oncologie was founded on 22 May 2017.

Who are the directors of Dr. Vulsteke Christof, medische oncologie?

According to the 2025 annual accounts, the directors of Dr. Vulsteke Christof, medische oncologie are: Christof Vulsteke.

Is Dr. Vulsteke Christof, medische oncologie a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 22 May 2017; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Dr. Vulsteke Christof, medische oncologie make in 2025?

Dr. Vulsteke Christof, medische oncologie posted a profit after taxes of € 101,893 in financial year 2025.

What is the revenue of Dr. Vulsteke Christof, medische oncologie?

As a small company, Dr. Vulsteke Christof, medische oncologie is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 236,689.

Dr. Vulsteke Christof, medische oncologie (Private Limited)

Dossier Dr. Vulsteke Christof, medische oncologie, printed on 1 November 2026 from databakkes.be/en/0675919556/dr-vulsteke-christof-medische-oncologie. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 11 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

Dr. Vulsteke Christof, medische oncologie from Deerlijk, company number BE0675919556, closed financial year 2025 with a result of € 101,893 after tax. For that financial year Dr. Vulsteke Christof, medische oncologie recorded a gross margin of € 236,689 and equity of € 18,600. Compared with financial year 2024, the result moved from € 110,684 to € 101,893. The company is profitable. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on December 23, 2025.

What it is worth Healthy

€ 18,600

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 101,893

▼ 8% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 22,071

▼ 74% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 101,893 paid out

100 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 7,852

▼ 18% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 2 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 153,829

▼ 32% vs 2024

€ 73,291 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.

Owed to suppliers

€ 6,125

▲ 64% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 813

▼ 96% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 210,699 Gross margin 2022: € 210,699 First fiscal year in the series	€ 217,147 Gross margin 2023: € 217,147 ▲ 3% vs 2022 (€ 210,699) Favourable step	€ 246,099 Gross margin 2024: € 246,099 ▲ 13% vs 2023 (€ 217,147) Favourable step	€ 236,689 Gross margin 2025: € 236,689 ▼ 4% vs 2024 (€ 246,099) Unfavourable step	▼ 4%
Profit after taxes	€ 85,203 Profit after taxes 2022: € 85,203 First fiscal year in the series	€ 85,495 Profit after taxes 2023: € 85,495 Unchanged (€ 85,203) Favourable step	€ 110,684 Profit after taxes 2024: € 110,684 ▲ 29% vs 2023 (€ 85,495) Favourable step	€ 101,893 Profit after taxes 2025: € 101,893 ▼ 8% vs 2024 (€ 110,684) Unfavourable step	▼ 8%
Equity	€ 244,676 Equity 2022: € 244,676 First fiscal year in the series	€ 241,872 Equity 2023: € 241,872 ▼ 1% vs 2022 (€ 244,676) Unfavourable step	€ 18,600 Equity 2024: € 18,600 ▼ 92% vs 2023 (€ 241,872) Unfavourable step	€ 18,600 Equity 2025: € 18,600 Unchanged (€ 18,600) Unchanged
Total debts	€ 384,695 Total debts 2022: € 384,695 First fiscal year in the series	€ 327,648 Total debts 2023: € 327,648 ▼ 15% vs 2022 (€ 384,695) Favourable step	€ 479,708 Total debts 2024: € 479,708 ▲ 46% vs 2023 (€ 327,648) Unfavourable step	€ 319,834 Total debts 2025: € 319,834 ▼ 33% vs 2024 (€ 479,708) Favourable step	▼ 33%
Cash	€ 59,880 Cash 2022: € 59,880 First fiscal year in the series	€ 67,252 Cash 2023: € 67,252 ▲ 12% vs 2022 (€ 59,880) Favourable step	€ 83,894 Cash 2024: € 83,894 ▲ 25% vs 2023 (€ 67,252) Favourable step	€ 22,071 Cash 2025: € 22,071 ▼ 74% vs 2024 (€ 83,894) Unfavourable step	▼ 74%
Land & buildings	€ 159,661 Land & buildings 2022: € 159,661 First fiscal year in the series	€ 161,555 Land & buildings 2023: € 161,555 ▲ 1% vs 2022 (€ 159,661) Unchanged	€ 145,186 Land & buildings 2024: € 145,186 ▼ 10% vs 2023 (€ 161,555) Unchanged	€ 134,969 Land & buildings 2025: € 134,969 ▼ 7% vs 2024 (€ 145,186) Unchanged	▼ 7%
Retained profit	€ 226,076 Retained profit 2022: € 226,076 First fiscal year in the series	€ 223,272 Retained profit 2023: € 223,272 ▼ 1% vs 2022 (€ 226,076) Unfavourable step	€ 0 Retained profit 2024: € 0 ▼ 100% vs 2023 (€ 223,272) Unfavourable step	€ 0 Retained profit 2025: € 0 Unchanged (€ 0) Unchanged
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 88,300 Dividend 2023: € 88,300 Unchanged (€ 0) Unchanged	€ 333,955 Dividend 2024: € 333,955 ▲ 278% vs 2023 (€ 88,300) Unchanged	€ 101,893 Dividend 2025: € 101,893 ▼ 69% vs 2024 (€ 333,955) Unchanged	▼ 69%
Bank debt	€ 367,784 Bank debt 2022: € 367,784 First fiscal year in the series	€ 297,438 Bank debt 2023: € 297,438 ▼ 19% vs 2022 (€ 367,784) Favourable step	€ 226,124 Bank debt 2024: € 226,124 ▼ 24% vs 2023 (€ 297,438) Favourable step	€ 153,829 Bank debt 2025: € 153,829 ▼ 32% vs 2024 (€ 226,124) Favourable step	▼ 32%
Balance sheet total	€ 629,372 Balance sheet total 2022: € 629,372 First fiscal year in the series	€ 569,520 Balance sheet total 2023: € 569,520 ▼ 10% vs 2022 (€ 629,372) Unchanged	€ 498,308 Balance sheet total 2024: € 498,308 ▼ 13% vs 2023 (€ 569,520) Unchanged	€ 338,434 Balance sheet total 2025: € 338,434 ▼ 32% vs 2024 (€ 498,308) Unchanged	▼ 32%

Key figures of Dr. Vulsteke Christof, medische oncologie, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.

What happened to Dr. Vulsteke Christof, medische oncologie?

What happened at Dr. Vulsteke Christof, medische oncologie in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Dec 23, 2025 New annual accounts for financial year 2025: profit of € 101,893 (▼ 8% vs 2024). Source: NBB ↗
May 22, 2017 New establishment in Gent. KBO
2017 Christof Vulsteke became a director. NBB
May 22, 2017 Start of the company according to the CBE. KBO

In short

From € 85,203 profit in 2022 to € 101,893 profit in 2025.

Paid € 120,316 in corporate taxes since 2022.

Best year ever: 2024, with € 110,684 profit.

Paid out € 524,148 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Christof Vulsteke

Dr. Vulsteke Christof, medische oncologie

Behind Dr. Vulsteke Christof, medische oncologie is Christof Vulsteke.

Directors

According to the 2025 annual accounts

Christof Vulsteke

Director

since 2017

Establishments

Establishment units

Physical locations of this company

Registered office

Generaal Deprezstraat 2 D

8540 Deerlijk

2.264.674.539

Buitenring-Sint-Denijs 30

9000 Gent

Active since 22 May 2017

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0675.919.556

VAT number

BE 0675.919.556

Registered office

Generaal Deprezstraat 2 D, 8540 Deerlijk

Names & denominations

Dr. Vulsteke Christof, medische oncologie

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

22 May 2017

Peppol

Active · Active since 27 Mar 2026

Activities · NACE

Activiteiten van medisch specialisten

Speur- en ontwikkelingswerk op biotechnologisch gebied

View on CBE Public ↗ Annual accounts (NBB) ↗

Dr. Vulsteke Christof, medische oncologie

Warning lights

Financials

What happened to Dr. Vulsteke Christof, medische oncologie?

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions